Brian Law

Biomarker-directed repurposing of Omveloxolone for treatment of colon and pancreatic cancers

Isoform-Selective Disulfide Isomerase Inhibitors for Overcoming Drug Resistance

Novel Targeted Anticancer Agents from Marine Cyanobacteria

HER1-3 and Death Receptor protein folding as therapeutic vulnerabilities

Reducing racial disparity in breast cancer survival with a novel synthetic-lethal strategy

Optimizing novel small molecule activators of Death Receptor 5 for breast cancer therapy

Novel Breast Cancer Therapeutics Targeting a Unique Subset of Disulfide Isomerases

Toward IND-Enabling Studies for Novel Cancer Therapeutics that Inhibit the Disulfide Isomerases ERp44, PDIA1, and AGR2

Regulation of Death Receptor 5 folding and apoptotic signaling by AGR2

Tranexamic Class Antagonists (TXCAs)

Tranexamic Acid Activity Against Melanoma and Breast Cancer

Dual mechanisms of DDA antitumor activity: Induction of tumor cell apoptosis and vascular disruption

A new approach for eradicating metastatic, drug-resistant breast cancers

Synthetic lethal strategy for killing EGFR+/HER2+ cancers

Novel agents that simultaneously downregulate Her2, EGFR, and Her3

CDCP1 as a therapeutic target in the dissemination of a

Nuovo Biologics Testing

Preventing Basal Breast Cancer Recurrence